AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03373877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.
Study NCT04232085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Preparative regimen
Study NCT04232085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Preparative regimen
Study NCT04232085 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Total Body Irradiation
Description: Preparative regimen
Study NCT04232085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: GVHD prophylaxis
Study NCT03870230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device
Study NCT01484171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: idarubicin 10-12 mg/m2 for three days
Study NCT01484171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microtransplantation
Description: idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
Study NCT02675426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet; Oral
Study NCT04232085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: GVHD prophylaxis
Study NCT02675426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral
Study NCT04296461 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Welgenaleucel
Description: Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
Study NCT03625817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mountainous setting
Description: The mountainous setting is characterized by lower temperatures (about 8-10C ambient air temp.) than those in urban setting, also having >800m altitude.Each period will last for 1 week with a wash out period of minimum 2 days. Continuous skin temperature and ambient temperature monitoring will take place in the last day of each period, towards the end. During the 2 sampling days, 24-hour urine voids will be collected in different vials. Participants will be required to fulfill a diary with their daily activities, meal times, collection of urine times, sleep/wake times and times of leaving/entering a closed environment.
Study NCT03870230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pattern Electroretinography (pERG)
Description: to assess the neuronal function of the retina, pattern ERG will be performed
Study NCT03870230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: to assess the morphology of the retina, OCT will be performed
Study NCT03870230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Speckle Flowgraphy (LSFG)
Description: to assess retinal blood flow, LSFG will be performed
Study NCT02846987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Study NCT03735966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus trastuzumab and docetaxel and carboplatin
Description: pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles
Study NCT03613857 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Description: 8 tablets 75 mg clopidogrel loading dose before PCI
Study NCT03613857 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor 90mg
Description: 2 tablets 90 mg brilique before PCI
Study NCT03070522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: oral prednisone for 7 days during pulmonary exacerbation
Study NCT03070522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT03379025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic cigarette
Description: electronic cigarette and cartridge refills (also known as pods)
Study NCT03379025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette
Description: electronic cigarette and cartridge refills (also known as pods)
Study NCT02053948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pursestring Wound Closure
Study NCT02053948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gunsight Skin Incision and Closure Technique
Study NCT04225208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AZD4205, single 50 mg oral dose administrated on day 1
Description: Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
Study NCT03002181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: 70 minute education session.
Study NCT03850119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofat injection
Description: Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.
Study NCT03894449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotic + Iron Forificant
Description: A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
Study NCT03894449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prebiotic + Iron Forificant
Description: A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
Study NCT04232085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: GVHD prophylaxis
Study NCT03859323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.
Study NCT03859323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
Study NCT04054583 — intervention group
Intervention type: OTHER
Intervention: Renovation of long-term residential care living spaces
Description: Living spaces of the long term care facility will be renovated.
Study NCT02648698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
Study NCT04458584 — intervention group
Intervention type: PROCEDURE
Intervention: Trapeziectomy with ligament reconstruction (I; LRTI)
Description: Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)
Study NCT04458584 — intervention group
Intervention type: PROCEDURE
Intervention: Trapeziectomy with suture suspensionplasty (II; SS)
Description: Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)
Study NCT04458584 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic Trapeziectomy (III; AT)
Description: Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
Study NCT02295111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EA treatment
Description: Electro acupuncture and traditional Chinese Medicine Health consult
Study NCT02295111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCM health consult
Description: Traditional Chinese Medicine Health Consult without needling
Study NCT02295111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard NHS care
Study NCT02081300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate, LPCN 1021
Study NCT02081300 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical testosterone gel 1.62 %
Study NCT03021382 — intervention group
Intervention type: OTHER
Intervention: data collection, non-intervention
Study NCT02337647 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DCDC App
Description: The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
Study NCT03380442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin ingested orally
Study NCT03380442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine (Ketalar)
Description: Ketamine administered intranasally
Study NCT00354705 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Two questionnaires taking 30 minutes to complete.
Study NCT03956017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinone
Description: Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
Study NCT03956017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
Study NCT05363033 — intervention group
Intervention type: DEVICE
Intervention: sarcopenia nursing guidance mobile application was developed
Description: The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
Study NCT03725982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laevo ®
Description: A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).
Study NCT01883297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Re-stimulated tumor-infiltrating lymphocytes (TILs)
Description: Intravenous infusions: Dose level 1 (3 patients): 3x10\^7 TILs (with maximum 3x10\^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10\^8 TILs (with maximum 1x10\^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10\^8 TILs (with maximum 3x10\^8 autologous dendritic cells)
Study NCT01883297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
Study NCT01883297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
Study NCT01682447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive Pulmonary Rehabilitation Program
Description: Fulltime pulmonary rehabilitation program. Duration: 12 weeks
Study NCT01863368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preservative-free saline solution eyedrops
Description: 1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
Study NCT01863368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preservative-free saline solution eyedrops
Description: 1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
Study NCT01863368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane® ULTRA lubricant eyedrops
Study NCT01863368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIVE® lubricating eyedrops
Study NCT02195219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open reduction internal fixation
Description: MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
Study NCT02195219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sling rest and early functional recovery
Description: Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
Study NCT00960284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT00960284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00960284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Given IV
Study NCT00960284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00960284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT04083950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vivotif Typhoid Oral Vaccine
Description: One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
Study NCT04083950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (Positive Control)
Description: Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
Study NCT01498406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (\<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
Study NCT01498406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (\<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
Study NCT00304278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Description: 150 mg daily X 7 weeks
Study NCT00304278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Cisplatin (PLAT)
Description: 1 dose (150 mg/sq) per week X 4 weeks
Study NCT02543736 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Instrumented Treadmill System
Description: Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
Study NCT02505711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homestead Food Production program
Description: Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
Study NCT02544945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed bolus
Description: Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
Study NCT03725982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Laevo ®
Description: The subjects will not wear any supporting device to perform the experiment, which serves as the control condition.
Study NCT02544945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard bolus
Description: A standard 5mm-thick piece of rubber is placed on the patient's chest wall
Study NCT01259518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIN2755
Description: In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
Study NCT01259518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIN2755
Description: In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
Study NCT04677582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vidas Activas, famiLias saludablEs (VALE)
Description: Families and Children allocated to the intervention will receive weekly group-based meetings over a 10-week period consisting of education and activities on healthy lifestyles. Graduate students/Research Assistants trained in nutrition, exercise and clinical psychology will lead the meetings. All activities will be culturally relevant (i.e. cooking healthy Latino recipes) and Spanish speaking students will be recruited to deliver the intervention. Participants will be involved on deciding activities and projects and while some sessions will meet as a family group with parents/guardians, others will meet separately.
Study NCT02601911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
Study NCT02601911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
Study NCT02601911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group receive the caplet including placebo 45 minutes before the injection.
Study NCT00524134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol-CR
Description: Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
Study NCT03808506 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin
Description: Stool test to look at baseline burden of inflammation
Study NCT04576208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules
Study NCT04576208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidiarrheal prophylaxis
Description: Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
Study NCT04856995 — intervention group
Intervention type: OTHER
Intervention: exposure to surgical smoke during surgery
Description: No intervention was made. During the surgery, complaints and throat cultures were taken before and after exposure to surgical smoke. Simultaneously, 45 air samples are taken in the operating room before, during and after the operation.
Study NCT03526952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Delivered Intervention for Sexual Re-Adjustment
Description: Couples will meet with a therapist via video-conferencing for two 1.5-hr sessions. The therapist will facilitate couples' communication about their sexual and intimate relationship while providing psychoeducation about couple coping and sexuality after cancer and with an ostomy. Discussion will focus on current concerns, motivations for sex, relational strengths, and intimacy and sensual pleasure. Couples will also be encouraged to practice a sensate focusing exercise between sessions.
Study NCT03526952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Educational Material
Description: Couples will receive written educational material for patients coping with changes in intimacy and sexuality when living with a permanent ostomy. This educational material is published by the United Ostomy Associations of America, Inc. and is available for free download from their website. Couples will have two weeks to read this material.
Study NCT02239887 — intervention group
Intervention type: DEVICE
Intervention: WaveCrest LAA occlusion device
Description: Left Atrial Appendage Occlusion
Study NCT04365946 — intervention group
Intervention type: PROCEDURE
Intervention: Gastroscopy
Description: Upper GI endoscopy and biopsy
Study NCT01767545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone implant
Study NCT01767545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab